According to demographic provision, the world population will soon reach 6 billions. It is therefore urgent to increase women's access to well tolerated, efficient, low cost contraceptives. The primary goal is to inform women on their reproductive health and on the use of contraceptives. Secondly, new molecules should be shortly available: low dose estroprogestins containing new non androgenic progestins and 17 beta-estradiol, RU 486 as a post-coïtal pill, levonorgestrel or desogestrel containing IUDs. The daily intake of low dose antiprogestins to interfere with endometrial maturation is also currently studied. In the future, anti-FSH molecules or tissue-specific steroids could be designed.